Nutriband Develops Innovative Abuse-Deterrent Fentanyl Patch Amid Opioid Crisis
May 9th, 2025 1:05 PM
By: Advos Staff Reporter
Nutriband is advancing a groundbreaking transdermal fentanyl patch designed to reduce opioid misuse, responding to critical FDA regulatory changes and the ongoing public health challenge of opioid addiction.
Nutriband Inc. is developing AVERSA™, a pioneering abuse-deterrent transdermal fentanyl patch, positioning itself at the forefront of innovative pharmaceutical solutions to the ongoing opioid crisis. The company's technological advancement comes at a critical time when regulatory agencies are intensifying efforts to combat opioid misuse and addiction.
Recent FDA regulatory changes underscore the urgent need for safer drug delivery methods. In early 2025, the agency approved Journavx, a non-opioid painkiller, and mandated new safety protocols for opioid manufacturers, including prepaid mail-back envelopes for medication disposal and enhanced warning labels highlighting addiction risks.
Nutriband's AVERSA™ technology represents a significant response to these regulatory shifts. By developing an abuse-deterrent fentanyl patch, the company aims to provide a more responsible approach to pain management that minimizes the potential for drug misuse and addiction.
Strategic partnerships, such as the collaboration with Kindeva, and a strengthened global intellectual property portfolio position Nutriband to potentially transform opioid delivery. The company's innovation could offer healthcare providers and patients a more secure method of administering powerful pain medications.
As the pharmaceutical landscape continues to evolve, Nutriband's commitment to developing safer opioid delivery systems could play a crucial role in addressing the complex challenges of pain management and substance abuse prevention.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
